Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Old News
View:
Post by LittleLadyPhD on May 03, 2016 8:54am

Old News

Frogger2: Your cut-and-paste is from a paper Kamat co-authored published online in Jan 2016 Journal of Clin Oncol: summary of trial design/endpoints for any new drug for NMIBC. The second cut-and-paste is his presentation at EAU16 summarizing the results from the P3 MCNA trial (pub Journal of Urol Apr 2015). You can't make 2+2=5. We're all on hold until we get real news (May 9?)...
Comment by Frogger2 on May 03, 2016 11:41am
Actually, the trial protocol is very important to Telesta because it clearly defines what is required, do you recall what they are asking the FDA for regarding trial protocol?. If adopted this makes the data from 301 relevant since it is in line with the BCG non responsive group. Your assumption that Kamat was presenting old information is a surprise, why would a doctor with his credentials do ...more  
TELESTA THERAPEUTICS INC